These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 38892306)
1. Shedding Light on Dark Chemical Matter: The Discovery of a SARS-CoV-2 M Peralta-Moreno MN; Mena Y; Ortega-Alarcon D; Jimenez-Alesanco A; Vega S; Abian O; Velazquez-Campoy A; Thomson TM; Pinto M; Granadino-Roldán JM; Santos Tomas M; Perez JJ; Rubio-Martinez J Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892306 [TBL] [Abstract][Full Text] [Related]
2. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach. Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862 [TBL] [Abstract][Full Text] [Related]
3. Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity. Hamdy R; Fayed B; Mostafa A; Shama NMA; Mahmoud SH; Mehta CH; Nayak Y; M Soliman SS Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445763 [TBL] [Abstract][Full Text] [Related]
4. Computational Screening Using a Combination of Ligand-Based Machine Learning and Molecular Docking Methods for the Repurposing of Antivirals Targeting the SARS-CoV-2 Main Protease. Yuda GPWC; Hanif N; Hermawan A Daru; 2024 Jun; 32(1):47-65. PubMed ID: 37907683 [TBL] [Abstract][Full Text] [Related]
5. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach. Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135 [TBL] [Abstract][Full Text] [Related]
6. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease. Marinho EM; Batista de Andrade Neto J; Silva J; Rocha da Silva C; Cavalcanti BC; Marinho ES; Nobre Júnior HV Microb Pathog; 2020 Nov; 148():104365. PubMed ID: 32619669 [TBL] [Abstract][Full Text] [Related]
7. Exploring epigenetic drugs as potential inhibitors of SARS-CoV-2 main protease: a docking and MD simulation study. Uzuner U; Akkus E; Kocak A; Çelik Uzuner S J Biomol Struct Dyn; 2024 Aug; 42(13):6892-6903. PubMed ID: 37458994 [TBL] [Abstract][Full Text] [Related]
8. Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease. Manelfi C; Gossen J; Gervasoni S; Talarico C; Albani S; Philipp BJ; Musiani F; Vistoli G; Rossetti G; Beccari AR; Pedretti A Molecules; 2021 Feb; 26(4):. PubMed ID: 33557115 [TBL] [Abstract][Full Text] [Related]
9. Investigation of bio-active Amaryllidaceae alkaloidal small molecules as putative SARS-CoV-2 main protease and host TMPRSS2 inhibitors: interpretation by Bhowmick S; Mistri TK; Khan MR; Patil PC; Busquets R; Ashif Ikbal AM; Choudhury A; Roy DK; Palit P; Saha A J Biomol Struct Dyn; 2024 Sep; 42(14):7107-7127. PubMed ID: 37482789 [TBL] [Abstract][Full Text] [Related]
10. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and Identification of Novel Potential Molecules Against COVID-19 Main Protease Through Structure-Guided Virtual Screening Approach. El Bakri Y; Anouar EH; Ahmad S; Nassar AA; Taha ML; Mague JT; El Ghayati L; Essassi EM Appl Biochem Biotechnol; 2021 Nov; 193(11):3602-3623. PubMed ID: 34324152 [TBL] [Abstract][Full Text] [Related]
12. Identification of Pyrazole Derivatives of Usnic Acid as Novel Inhibitor of SARS-CoV-2 Main Protease Through Virtual Screening Approaches. Roney M; Singh G; Huq AKMM; Forid MS; Ishak WMBW; Rullah K; Aluwi MFFM; Tajuddin SN Mol Biotechnol; 2024 Apr; 66(4):696-706. PubMed ID: 36752937 [TBL] [Abstract][Full Text] [Related]
13. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study. Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867 [TBL] [Abstract][Full Text] [Related]
14. Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors. Breidenbach J; Lemke C; Pillaiyar T; Schäkel L; Al Hamwi G; Diett M; Gedschold R; Geiger N; Lopez V; Mirza S; Namasivayam V; Schiedel AC; Sylvester K; Thimm D; Vielmuth C; Phuong Vu L; Zyulina M; Bodem J; Gütschow M; Müller CE Angew Chem Int Ed Engl; 2021 Apr; 60(18):10423-10429. PubMed ID: 33655614 [TBL] [Abstract][Full Text] [Related]
15. Computational discovery of dual potential inhibitors of SARS-CoV-2 spike/ACE2 and M Bekono BD; Onguéné PA; Simoben CV; Owono LCO; Ntie-Kang F Eur Biophys J; 2024 Aug; 53(5-6):277-298. PubMed ID: 38907013 [TBL] [Abstract][Full Text] [Related]
16. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19. Joshi T; Sharma P; Joshi T; Pundir H; Mathpal S; Chandra S Mol Divers; 2021 Aug; 25(3):1665-1677. PubMed ID: 32602074 [TBL] [Abstract][Full Text] [Related]
17. Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2. Fischer A; Sellner M; Mitusińska K; Bzówka M; Lill MA; Góra A; Smieško M Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669738 [TBL] [Abstract][Full Text] [Related]
18. Selection of SARS-CoV-2 main protease inhibitor using structure-based virtual screening. Hakami AR; Bakheit AH; Almehizia AA; Ghazwani MY Future Med Chem; 2022 Jan; 14(2):61-79. PubMed ID: 34814706 [No Abstract] [Full Text] [Related]
19. Screening of Potential Inhibitors Targeting the Main Protease Structure of SARS-CoV-2 via Molecular Docking, and Approach with Molecular Dynamics, RMSD, RMSF, H-Bond, SASA and MMGBSA. da Fonseca AM; Caluaco BJ; Madureira JMC; Cabongo SQ; Gaieta EM; Djata F; Colares RP; Neto MM; Fernandes CFC; Marinho GS; Dos Santos HS; Marinho ES Mol Biotechnol; 2024 Aug; 66(8):1919-1933. PubMed ID: 37490200 [TBL] [Abstract][Full Text] [Related]
20. Bung N; Krishnan SR; Bulusu G; Roy A Future Med Chem; 2021 Mar; 13(6):575-585. PubMed ID: 33590764 [No Abstract] [Full Text] [Related] [Next] [New Search]